Publications:437
Accepting New Patients
Mount Sinai DoctorsTreats Adults
Accepting New PatientsRonald Hoffman, MD
Internal Medicine, Hematology-Oncology
No Patient Experience Ratings
Book an Appointment
About Me
Ronald Hoffman, MD, is the Albert A. and Vera G. List Professor of Medicine, Professor of Medicine (Hematology and Medical Oncology), and Director of the Myeloproliferative Disorders Research Program. He founded this program in 2007 and has developed it into one of the most effective and well respected programs in the world dealing with myeloproliferative disorders. His interest in this group of blood cancers stemmed from his time as a fellow in Hematology at Mount Sinai (1974-1977.), where he worked with numerous Mount Sinai faculty including Drs. Ralph Zalusky, Esmail Zanjani, and Lewis Wasserman. After holding administrative positions at several other institutions, Dr. Hoffman retuned to Mount Sinai in 2007 to work in the laboratory and the clinics in order to focus on translational research in blood cancers. He continues to care for patients with myeloproliferative neoplasms on a daily basis.
Dr. Hoffman is a leader in stem cell research. His studies of human hematopoietic stem cells and progenitor cells in myeloproliferative neoplasms have led to many therapeutic advances. He has also pioneered a unique method of increasing the number of cord blood stem cells used to treat patients with blood cancers and blood disorders.
In 2003, Dr. Hoffman founded the Myeloproliferative Neoplasm Research Consortium, a multi-institutional program project grant funded by the National Cancer Institute, which is committed to research in and treatment of myeloproliferative neoplasms. The Consortium involves 12 institutions throughout the United States and Canada and is focused on identifying new therapies for patients with myeloproliferative neoplasms and evaluating their effectiveness in carefully constructed clinical trials
Dr. Hoffman has served as president of the American Society of Hematology and the International Society for Experimental Hematology.
Dr. Hoffman is the editor of Hematology: Basic Principles and Practice. He conceptualized and organized this leading textbook of hematology, which is currently entering its eighth edition. He is an author on almost 500 peer-reviewed publications and 130 books/book chapters/reviews. He has also served as the editor of the journal Experimental Hematology.
Dr. Hoffman has mentored countless post-doctoral fellows and junior faculty, and serves as advisor to the Mentoring Committee for junior faculty at the Icahn School of Medicine at Mount Sinai.
In 2017 Dr. Hoffman received the prestigious Mentor Award from American Society of Hematology in recognition of his outstanding commitment to the training and career development of early-career hematologists and advancing research and patient care in hematology.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
About Me
Ronald Hoffman, MD, is the Albert A. and Vera G. List Professor of Medicine, Professor of Medicine (Hematology and Medical Oncology), and Director of the Myeloproliferative Disorders Research Program. He founded this program in 2007 and has developed it into one of the most effective and well respected programs in the world dealing with myeloproliferative disorders. His interest in this group of blood cancers stemmed from his time as a fellow in Hematology at Mount Sinai (1974-1977.), where he worked with numerous Mount Sinai faculty including Drs. Ralph Zalusky, Esmail Zanjani, and Lewis Wasserman. After holding administrative positions at several other institutions, Dr. Hoffman retuned to Mount Sinai in 2007 to work in the laboratory and the clinics in order to focus on translational research in blood cancers. He continues to care for patients with myeloproliferative neoplasms on a daily basis.
Dr. Hoffman is a leader in stem cell research. His studies of human hematopoietic stem cells and progenitor cells in myeloproliferative neoplasms have led to many therapeutic advances. He has also pioneered a unique method of increasing the number of cord blood stem cells used to treat patients with blood cancers and blood disorders.
In 2003, Dr. Hoffman founded the Myeloproliferative Neoplasm Research Consortium, a multi-institutional program project grant funded by the National Cancer Institute, which is committed to research in and treatment of myeloproliferative neoplasms. The Consortium involves 12 institutions throughout the United States and Canada and is focused on identifying new therapies for patients with myeloproliferative neoplasms and evaluating their effectiveness in carefully constructed clinical trials
Dr. Hoffman has served as president of the American Society of Hematology and the International Society for Experimental Hematology.
Dr. Hoffman is the editor of Hematology: Basic Principles and Practice. He conceptualized and organized this leading textbook of hematology, which is currently entering its eighth edition. He is an author on almost 500 peer-reviewed publications and 130 books/book chapters/reviews. He has also served as the editor of the journal Experimental Hematology.
Dr. Hoffman has mentored countless post-doctoral fellows and junior faculty, and serves as advisor to the Mentoring Committee for junior faculty at the Icahn School of Medicine at Mount Sinai.
In 2017 Dr. Hoffman received the prestigious Mentor Award from American Society of Hematology in recognition of his outstanding commitment to the training and career development of early-career hematologists and advancing research and patient care in hematology.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
Clinical Focus
- Acute Myeloid Leukemia
- Essential Thrombocythemia
- Hematologic Malignancies
- Hematology
- Leukemia
- Myelodysplastic Syndromes
- Myelofibrosis
- Myeloproliferative Disorders
Education
MD, New York University School of Medicine
Residency, Internal Medicine
Montreal General Hospital
Residency, Internal Medicine
Stanford University School of Medicine
Fellowship, Hematology
Mount Sinai Hospital
Certifications
American Board of Internal Medicine
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.
- Ruttenberg Treatment Center1470 Madison Avenue, 3rd Floor, New York, NY, 10029
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease. Daniela Guisado, Sayali Talware, Xiaoli Wang, Andrew Davis, Elbek Fozilov, Aaron Etra, Jean Frederic Colombel, Christoph Schaniel, Christopher Tastad, John E. Levine, James L.M. Ferrara, Chuang Ling-Shiang, Ksenija Sabic, Shishir Singh, Bridget K. Marcellino, Ronald Hoffman, Judy Cho, Louis Cohen. Gut
- HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis: CHRONIC MYELOPROLIFERATIVE NEOPLASMS. Shivani Handa, Christoph Schaniel, Joseph Tripodi, Daiva Ahire, Md Babu Mia, Sophie Klingborg, Douglas Tremblay, Bridget K. Marcellino, Ronald Hoffman, Vesna Najfeld. Leukemia
- Diagnosis and Treatment of Polycythemia Vera: A Review. Douglas Tremblay, Marina Kremyanskaya, John Mascarenhas, Ronald Hoffman. JAMA - Journal of the American Medical Association
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Hoffman during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Glycomimetics
- Silence Therapeutics
- Dexcel Pharma Technologies LTD
- AbbVie, Inc.
- Sumitomo Pharmaceuticals, Osaka,Japan
- Cellenkos, Inc.
- Protagonist Therapeutics, Inc
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Hoffman during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Glycomimetics
- Silence Therapeutics
- Dexcel Pharma Technologies LTD
- AbbVie, Inc.
- Sumitomo Pharmaceuticals, Osaka,Japan
- Cellenkos, Inc.
- Protagonist Therapeutics, Inc
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.